Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | GALR3 | O60755 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | GPR35 | Q9HC97 | 4/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.40 |
| ▸ | ERN1 | O75460 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2032952 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL6232013 | 0.85 | SMN1; SMN2 (0.52) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL22712664 | 0.83 | TDP1 (0.40) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL8812139 | 0.82 | GPR35 (0.49) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL2135932 | 0.76 | GPR35 (0.64) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL18688898 | 0.75 | SMN1; SMN2 (0.44) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL25382014 | 0.74 | SMN1; SMN2 (0.47) | SMN1; SMN2MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL11529022 | 0.74 | TDP1 (0.50) | SMN1; SMN2MEN1GALR3HTTKMT2A | |
| SCHEMBL10906475 | 0.74 | CA2 (0.56) | SMN1; SMN2HTTTSHRNPSR1ALDH1A1 | |
| SCHEMBL3083253 | 0.73 | GPR35 (0.71) | SMN1; SMN2MEN1KMT2AGPR35ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676722-B2 | Industrial process for making an Ivacaftor and its intermediates | OPTIMUS DRUGS PRIVATE LIMITED (IN) | 2017-06-13 | — | — | US | claimed |
| WO-2017060779-A1 | INDUSTRIAL PROCESS FOR MAKING AN IVACAFTOR AND ITS INTERMEDIATES | OPTIMUS DRUGS (P) LIMITED (IN) | 2017-04-13 | — | — | WO | claimed |
| US-20170096397-A1 | Industrial Process for Making an Ivacaftor and its Intermediates | OPTIMUS DRUGS PRIVATE LIMITED (IN) | 2017-04-06 | — | — | US | claimed |
| CN-119033710-A | Pharmaceutical composition for treating cystic fibrosis | 弗特克斯药品有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-111818918-B | Pharmaceutical composition for treating cystic fibrosis | 弗特克斯药品有限公司 | 2024-08-23 | — | — | CN | disclosed |
| US-9676722-B2 | Industrial process for making an Ivacaftor and its intermediates | OPTIMUS DRUGS PRIVATE LIMITED (IN) | 2017-06-13 | — | — | US | disclosed |
| WO-2017060779-A1 | INDUSTRIAL PROCESS FOR MAKING AN IVACAFTOR AND ITS INTERMEDIATES | OPTIMUS DRUGS (P) LIMITED (IN) | 2017-04-13 | — | — | WO | disclosed |
| US-20170096397-A1 | Industrial Process for Making an Ivacaftor and its Intermediates | OPTIMUS DRUGS PRIVATE LIMITED (IN) | 2017-04-06 | — | — | US | disclosed |
| US-8269029-B2 | Water repellent metal-organic frameworks, process for making and uses regarding same | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100075123-A1 | WATER REPELLENT METAL-ORGANIC FRAMEWORKS, PROCESS FOR MAKING AND USES REGARDING SAME | University of Illinois - Office of Technology Management (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096397-A1 | Industrial Process for Making an Ivacaftor and its Intermediates | COASY, SLC10A2, ACVR1 | SMN1; SMN2 2684/4885MEN1 3497/4885GALR3 4051/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.